Published in final edited form as:

Breast Cancer Res Treat. 2012 February ; 132(1): 235–242. doi:10.1007/s10549-011-1906-3.

Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients

Sarika Jain¹, Maureen M. Ward¹, Jennifer O'Loughlin¹, Marissa Boeck¹, Naomi Wiener¹, Ellen Chuang¹, Tessa Cigler¹, Anne Moore¹, Diana Donovan¹, Christina Lam¹, Marta V. Cobham¹, Sarah Schneider¹, Paul Christos², Rebecca N. Baergen³, Alexander Swistel⁴, Maureen E. Lane¹, Vivek Mittal⁵, Shahin Rafii⁶, and Linda T. Vahdat¹

¹Department of Medicine, Weill Cornell Medical College, New York, NY, United States, 10065

²Department of Public Health, Weill Cornell Medical College, New York, NY, United States, 10065

³Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, United States, 10065

⁴Department of Surgery, Weill Cornell Medical College, New York, NY, United States, 10065

⁵Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, NY, United States, 10065

⁶Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, United States, 10065

Abstract

Purpose—Animal models have demonstrated the critical role of bone marrow-derived VEGFR1⁺ hematopoietic progenitor cells (HPCs) and VEGFR2⁺ endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients.

Experimental Design—132 patients with stages 1 to 4 BC were enrolled on 2 studies. Circulating CD45⁺/CD34⁺/VEGFR1⁺ HPCs and CD45^{dim}/CD133⁺/VEGFR2⁺ EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in 1) patients without overt disease that relapsed and 2) metastatic patients according to response by RECIST.

Results—At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/mL (range) increased from 645.8 (23.5-1914), $p=0.016$, followed by an increase in median EPC/mL from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), $p=0.016$, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/mL increased

Corresponding author: Linda Vahdat, MD, Weill Cornell Medical College Iris Cantor Breast Center, 425 East 61st, 8th floor, New York, NY 10065, Phone: 212-821-0644, Fax: 212-821-0758, ltv2001@med.cornell.edu.

Presented in part at the Annual Meeting of the American Association for Cancer Research, April 2 – 6, 2011.

from 1696 (10-16470) to 5124 (374-77605), $p=0.0009$, and median EPC/mL increased from 26 (0-560) to 71 (0-615) prior to progression, $p=0.10$. In patients with responding disease, median HPC/mL decreased from 6147 (912-85070) to 633 (47-18065), $p=0.05$, and EPC/mL decreased from 46 (0-197) to 23 (0-105), $p=0.41$, at response. There were no significant changes in these cells over time in patients with stable disease.

Conclusions—Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.

Keywords

breast cancer; metastasis; VEGFR1⁺; VEGFR2⁺; angiogenic switch

Introduction

Breast cancer remains the most commonly diagnosed cancer among women and the second leading cause of cancer mortality in the United States (1). Despite major advances in adjuvant therapy for early-stage breast cancer, patients still have a 20 to 50% chance of relapse over 10 years (2). Metastasis, the final step of cancer progression, is responsible for most cancer-related deaths and may occur after an extraordinarily long period of time after initial diagnosis and treatment (3, 4). Traditionally, probability of metastases has been correlated to tumor size and nodal status in breast cancer, but recent data suggest that molecular subtype may ultimately trump all traditional prognostic factors with the basal and HER2/neu intrinsic subtypes having the worst prognosis (5–8). Though great strides have been made in delineating risk factors associated with recurrence, a reliable test to herald a clinical relapse does not exist. Several serum-based tumor markers are available in clinical practice for breast cancer, however a clinical intervention when a tumor marker becomes newly abnormal is usually too late to prevent an impending relapse. Therefore, American Society of Clinical Oncology (ASCO) guidelines do not recommend routine screening with tumor markers in adjuvant breast cancer patients (9).

It is well established that tumor angiogenesis, the process of new blood vessel formation from preexisting vasculature, as well as differentiation and migration of endothelial cells, plays a crucial role in the growth and metastasis of tumors (10, 11). However less is known regarding the mechanisms that allow the transition from dormant, or occult, cancer cells to overt clinical relapse in cancer patients. Emerging evidence from preclinical models suggests that tumor-derived signals stimulate the quiescent bone marrow compartment, resulting in the expansion and mobilization of bone marrow-derived (BMD) VEGFR1⁺ hematopoietic progenitor cells (HPCs) and VEGFR2⁺ endothelial progenitor cells (EPCs), among others. HPCs home to the target organ and form clusters, or *pre-metastatic niches*, providing a permissive local microenvironment for the recruitment of incoming tumor cells and the establishment of micrometastases. EPCs are then recruited to the periphery of the micrometastatic lesions where they modulate the *angiogenic switch*, the transition from avascular micrometastatic lesions to vascularized macrometastatic disease. In these murine models, inhibition of VEGFR1⁺ significantly reduces HPC localization to the premetastatic niche and development of metastasis. Similarly, blocking EPC mobilization strongly inhibits vasculogenesis and impairs the formation of macrometastases (12–14).

The contribution of HPCs and EPCs to human cancer progression and pathogenesis is less well understood. HPCs have been implicated in defining the premetastatic niche in axillary lymph nodes of breast cancer patients and pelvic lymph nodes of prostate cancer patients (13, 15). Elevated EPCs have been observed in cancer patients versus healthy controls (16). EPCs have been also associated with advanced stage and worse prognosis in several hematologic and solid malignancies, and some but not all breast cancer studies (17–23).

Based on the preclinical data characterizing the angiogenic switch in murine model systems, we designed a study to characterize the angiogenic switch in a breast cancer population. We analyzed the temporal relationship of HPCs and EPCs in a series of breast cancer patients at high risk of recurrence based on traditional clinicopathologic factors. Furthermore, we explored whether quantitative changes in these cells could predict response to therapy in a well-annotated cohort of breast cancer patients receiving systemic therapy for advanced disease.

Materials and Methods

Patients with breast cancer were enrolled on one of two Institutional Review Board approved studies at Weill Cornell Medical College (WCMC) Iris Cantor Breast Cancer Center. Written informed consent was obtained in accordance with the Declaration of Helsinki.

Study population and design

Study 1—Patients with pathologically confirmed stage 1 to 4 invasive breast cancer were recruited from WCMC Iris Cantor Breast Cancer Center from March 2005 to July 2009 and divided into 2 cohorts:

Cohort 1: Patients with stage 1 to 3 breast cancer were enrolled following definitive surgery (lumpectomy and axillary evaluation or mastectomy) and prior to the initiation of adjuvant systemic therapy. Adjuvant systemic therapy was based on physician's choice and could consist of the following: chemotherapy, hormonal therapy, biologic and/or radiation therapy. Clinical specimens were obtained at the initiation of systemic therapy, halfway through systemic chemotherapy and every three months at routine follow-up thereafter.

Cohort 2: Patients with stage 4 breast cancer with established metastasis or with presentation of newly diagnosed stage 4 disease (*de novo* stage 4 breast cancer) were enrolled upon starting a new systemic therapy. Clinical specimens were obtained monthly and coincident with an imaging scan to assess response to therapy.

Study 2—Patients without evidence of breast cancer but at high risk of relapse with pathologically confirmed stage 2 or greater triple-negative breast cancer and any subtype of stage 3 or stage 4 breast cancer with no evidence of disease (stage 4 NED) were enrolled on a phase II trial of tetrathiomolybdate, a copper depletion compound at WCMC Iris Cantor Breast Cancer Center (NCT00195091, 0903-882) from July 2007 to June 2010. In this trial, clinical specimens were obtained on a monthly basis for up to two years.

Clinical Response

Response was based on Response Evaluation Criteria in Solid Tumors (RECIST) (24). Patients with progressive disease (PD) comprised the “progression of disease” group. Patients with complete response (CR) or partial response (PR) comprised the “responding disease” group. Patients with stable disease (SD) comprised the “stable disease” group.

HPC and EPC quantitation

Blood samples were obtained prior to chemotherapy administration. Ten to 20 mL of venous blood were collected in EDTA-containing tubes and processed within 12 hours. Laboratory evaluation of specimens in both studies was identical. Peripheral blood mononuclear cells were isolated by Ficoll density-gradient centrifugation. To quantitate circulating EPCs, cells were stained with CD133-PE (Miltenyi Biotec, Auburn, CA), VEGFR2-APC (R&D Systems, Minneapolis, MN), and CD45-PerCP (BD Biosciences, Franklin Lakes, NJ). To quantitate HPCs, cells were stained with CD34-FITC (BD Biosciences), VEGFR1-APC (R&D Systems), and CD45-PerCP (BD Biosciences). An aliquot of cells was also stained with the appropriate isotype controls (mouse anti-human IgG1k). Samples were analyzed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). Three hundred thousand events were collected in the nucleated cell gate (excludes debris and platelets). Data analysis was done using FlowJo software (FlowJo, Ashland, OR). A series of consecutive gates were made to include and exclude acquired events to quantitate specific populations such as CD45⁺, CD34⁺, VEGFR1⁺. The number of EPCs and HPCs per mL of blood was calculated as follows: $\text{HPC/mL} = (\# \text{ HPC events} / \# \text{ lymphocyte events}) \times \text{absolute lymphocyte count (lymphocytes/mL)}$. $\text{EPC/mL} = (\# \text{ EPC events} / \# \text{ lymphocyte events}) \times \text{absolute lymphocyte count (lymphocytes/mL)}$. See supplemental data for detailed gating strategy.

Definition of HPCs and EPCs

The definition of HPCs and EPCs was based on the phenotypes used by Bertolini et al (25, 26). HPCs were defined as CD45⁺, CD34⁺, VEGFR1⁺. EPCs were defined as CD45^{dim}, CD133⁺, VEGFR2⁺.

Statistical analysis

All analyses were performed in GraphPad Prism Version 5.0 (GraphPad Software, La Jolla, CA). Results were expressed as medians and range. In metastatic patients, baseline was defined as initiation of a new systemic therapy, and comparisons between baseline and post-response HPC and EPC values were made with the Wilcoxon signed-rank test. Comparisons between baseline and post-response absolute lymphocyte values were made with standard paired *t* test. In the patients who relapsed from a prior no evidence of disease state, baseline was defined as median of EPC and HPC values prior to EPC or HPC surge, and comparisons between baseline and “prior to relapse” were made with the Wilcoxon signed-rank test. All *P* values were two-sided with statistical significance evaluated at the 0.05 alpha level.

Results

One hundred thirty-two patients were enrolled on two studies, Fig. 1. Data from both studies were combined to analyze patients who entered the study without overt breast cancer and developed recurrence while on study (“relapsed group”: Study 1 [observational study]/ Cohort 1 and Study 2 [TM trial]). Patients with stage 4 breast cancer were grouped according to response by RECIST (Study 1/Cohort 2). Demographic variables are shown in Table I.

Of the 102 patients, who at study entry were without evidence of disease by physical examination, laboratory data, tumor markers or imaging, 10 patients developed overt breast cancer recurrence while on study. Three patients relapsed 1 to 2 months after study entry and were not included in the analysis. Of the seven evaluable patients, 3 were from Study 1 and 4 from Study 2. Four patients had stage 4 breast cancer without any evidence of disease (2 were estrogen receptor [ER] positive, 1 was HER2/neu positive, 1 was triple-negative), 2 patients had a prior diagnosis of stage 3C breast cancer (ER-positive and triple-negative) and 1 patient had a prior diagnosis of stage 2 breast cancer (triple-negative). The median primary tumor size was 3 cm (range 1.7 to 4.3 cm) and number of positive lymph nodes involved was 1 (range 1 to 42).

Incremental rise in VEGFR1⁺ HPCs and VEGFR2⁺ EPCs predicts relapse in patients with breast cancer who have no evidence of disease

In the 7 patients that developed relapse without prior evidence of disease, the median HPC/mL increased from baseline of 645.8 (range 23.5 to 1,914) to 2,899 (range 1,176 to 37,336) prior to relapse, $p=0.016$, Fig. 2A. Similarly, median EPC/mL increased from baseline of 21.3 (range 4.7 to 42.5) to 94.7 (range 28.2 to 201.3) immediately prior to relapse $p=0.016$, Fig. 2B.

In the 4 patients on Study 2, 3 patients had monthly specimens enabling a look at the temporal relation of HPCs and EPCs prior to relapse. In all 3 patients, an identical pattern in the progenitor cells emerged which heralded a relapse of breast cancer. An initial surge followed by a decline in HPCs and subsequent increase in EPCs preceded an overt recurrence, Fig. 3. In these patients, the median time between a surge in HPCs and EPCs prior to overt relapse was 6 months (range 4 to 8) and 1 month (range 1 to 2), respectively. Because the surge antedating relapse is between 4 and 8 months, the 3 patients who relapsed within 2 months of study entry were actively relapsing at that time hence were excluded from this analysis.

Incremental rise in VEGFR1⁺ HPCs and VEGFR2⁺ EPCs predicts clinical progression of disease in patients with breast cancer who are undergoing systemic therapy

Thirty patients with stage 4 breast cancer were enrolled into Cohort 2 of Study 1 and underwent evaluation at the initiation of therapy and at 3, 4 or 6-week intervals over the course of three years and 40 treatment cycles. Eight patients were not included in the final analysis due to death prior to subsequent sample collection (4 patients) and loss to follow up (4 patients). Of the 22 evaluable patients, systemic treatment included chemotherapy alone

(19 cycles), hormonal therapy (6 patients) and combinations of both with biologics (trastuzumab and/or lapatinib [11 patients], bevacizumab [2 patients], and dasatinib [2 patients]). HPCs and EPCs were analyzed in patients stratified by response as per RECIST (Table II). Patients with progressive disease representing 20 treatment cycles had a significant increase in HPCs preceding overt progression compared to the baseline values at the start of a new treatment, Fig. 4A/B. Median HPC/mL increased from baseline of 1,696 (range 10 to 16,470) to 5,124 (range 374 to 77,605) prior to progression, $p=0.0009$. Median EPC/mL increased from baseline of 26 (range 0 to 560) to 71 (range 0 to 615) prior to progression, $p=0.10$. The median time between baseline and the increase in HPCs and EPCs was 7.5 weeks (range 4 to 88). There were no significant changes in these patients' median absolute lymphocyte count (ALC)/ μL after receiving chemotherapy, 1,255 (range 500 to 2,800) at baseline and 1,450 (range 470 to 3,460) after chemotherapy, $p=0.08$.

Decrease in VEGFR1⁺ HPCs and VEGFR2⁺ EPCs predicts clinical response to systemic therapy.

Eleven patients with breast cancer metastases representing 12 treatment cycles that were responding to systemic therapy had a reduction in median HPC and EPC values, Fig. 4C/D. Median HPC/mL decreased from baseline of 6,147 (range 912 to 85,070) to 633 (range 47 to 18,065) at response, $p=0.05$. A trend was seen for decreased median EPC/mL; 46 (range 0 to 197) at baseline decreased to 23 (range 0 to 105) at response, $p=0.41$. The median time between baseline and the decrease in HPCs and EPCs was 6 weeks (range 4 to 23). Median ALC/ μL did not significantly change after chemotherapy in this group, 1,150 (range 600 to 3,400) at baseline and 1,250 (range 260 to 2,800) after chemotherapy, $p=0.53$.

Five patients with clinically stable disease after 8 treatment cycles did not have a significant change in either progenitor cells from baseline to a post-treatment time point, (median 9 weeks, range 8.5 to 32.5), Fig. 4E/F. HPC/mL remained stable at 1,309 (range 390 to 55,377) at baseline compared to 1,188 (range 135 to 20,690) at a post-treatment time point, $p=0.31$. EPC/mL decreased from 78 (range 11 to 484) at baseline to 29 (range 9 to 331) at a post-treatment time point, though this did not reach statistical significance, $p=0.15$. Similarly median ALC/ μL did not significantly change: 1,235 (range 1,000 to 2,300) to 1,450 (720 to 2,300), $p=0.7$.

Discussion

Understanding the metastatic process is critical in eradicating cancer deaths. In this prospective study, we begin to gather insight into the terminal events leading to the development of overt metastases in well-defined cohorts of breast cancer patients. We have demonstrated a substantial increase in the VEGFR1⁺ HPCs months before relapse followed by a surge in the VEGFR2⁺ EPCs immediately preceding an overt relapse of cancer. We postulate that the surge of HPCs in advance of the arrival of circulating EPCs represents initiation of the pre-metastatic niche, and an overt relapse occurs after EPCs "turn on" the angiogenic switch. This characteristic pattern was observed in patients without objective evidence of disease that relapsed as well as patients with established metastasis who progressed on therapy. In the 92 patients without evidence of disease who remained relapse-

free throughout the study, this pattern in HPCs and EPCs was not observed. We believe these observations confirm the preclinical models of metastases in breast cancer patients.

Furthermore, levels of circulating HPCs in patients with overt clinical metastases predicted therapeutic response. The change in HPCs was most significant in treatment-refractory tumors (progression of disease group) suggesting that active tumor neoangiogenesis is being driven by these cells. In fact, immediately prior to a patient's death, the levels of HPCs in addition to EPCs were several-fold higher than at any time earlier in their treatment course. In treatment-sensitive tumors (responding disease group), a significant reduction in HPCs was observed with therapy. The absolute lymphocyte count in these patients remained stable during treatment, therefore it is unlikely that the marrow suppressive effects of the chemotherapy contributed to the decrease in HPCs observed. A significant change in EPCs did not occur in either group, although there was a trend for increased EPCs in the progression of disease group and decreased EPCs in the responding group. This could be due to timing of the specimen as the angiogenic switch is a dynamic process, and a subsequent examination of EPCs even a week later may have revealed a further change that reached statistical significance. It is unclear if chemotherapy-induced EPC mobilization, described in mouse models and human patients may have contributed (27, 28). Taken together, we postulate that the change in HPCs might be the more robust marker to monitor for therapeutic response. Finally, as expected with the current model, in patients with disease that remained stable on therapy, there were no significant changes in either HPCs or EPCs.

It is important to acknowledge the difficulties in analyzing these progenitor cells. The lack of a consensus in defining the HPC and EPC phenotype or the optimal method to assay these cells may impact accurate quantification. The rarity of these cells in the peripheral circulation, constituting less than 0.0001–0.01% of peripheral circulating mononuclear cells, further underscores this difficulty (29). EPC levels may be affected by several factors including medications, growth factors, and common comorbidities such as cardiovascular disease (30, 31). Our data set is heavily annotated and controlled for these variables. Moreover, our study (and data from an ongoing unpublished study) suggest that the relationship between these two distinct populations of BMD progenitor cells might be more important than the absolute values.

There is a potential advantage for the use of HPCs and EPCs as a clinical biomarker over the use of existing serum-based biomarkers (e.g., CEA and CA15-3), as the latter probably does not predict relapse early in the metastatic process and is a relatively late-stage event. In our study, 9 of 14 patients in both the progression of disease and relapsed cohorts had an elevation of a tumor marker at least 2 months *after* the surge in HPCs. Conceivably, this change in BMD progenitor cells might represent a sufficiently early step in metastatic progression that allows for the opportunity to intervene with targeted therapy to promote maintenance of tumor dormancy and prevention of relapse or progression.

Several novel agents targeting BMD cells have been introduced into the clinical arena with promising data including cediranib, (pan-VEGFR inhibitor), ramucirumab (IMC-1121B, anti-VEGFR2 antibody) and IMC-18F1 (anti-VEGFR1 antibody) (32–34). Finally, Study 2 described here is an ongoing phase II clinical trial of an anti-angiogenic copper depletion

compound, which is attempting to modulate the angiogenic switch through copper-dependent mechanisms, in high risk for relapse breast cancer patients. We observed that patients who became adequately copper-depleted had a significant reduction in EPCs from baseline (35). A clinical trial investigating ramucirumab and IMC-18F1 in combination with capecitabine in women with metastatic breast cancer is underway and is expected to shed much insight into the role of these BMD progenitor cells and the effect of targeted therapy on outcome ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01234402) identifier: NCT01234402).

This is the first study to offer insight into the angiogenic switch *in vivo*, specifically in *de novo* relapse and progression of breast cancer metastases. Circulating HPCs and EPCs may serve as a biomarker to predict relapse or disease progression, as well as serve as a promising therapeutic target in those at high risk of relapse. Future avenues of research include a larger study to further define the temporal relationship and effect of different therapies on these cells.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We greatly appreciate the generous support from the following: Anne Moore Breast Cancer Research Fund, Stephen and Madeline Anbinder Foundation, Rozaliya Kosmandel Research Fund, Susan G Komen for the Cure, New York Community Trust, and Cancer Research and Treatment Fund. We would also like to thank the Weill Cornell Translational Core Laboratory, Rakhi Naik, MD for her initial contribution to the design of Study 1, and Dingchen Gao and Raul Catena for their valuable comments on this manuscript. Dr. Paul Christos was partially supported by the following grant: Clinical Translational Science Center (CTSC) (UL1-RR024996).

Financial support: Anne Moore Breast Cancer Research Fund, Stephen and Madeline Anbinder Foundation, Rozaliya Kosmandel Research Fund, Susan G Komen for the Cure, New York Community Trust, and Cancer Research and Treatment Fund. Paul Christos was partially supported by the following grant: Clinical Translational Science Center (CTSC) (UL1-RR024996).

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. *CA Cancer J Clin*. 2010; 60:277–300. [PubMed: 20610543]
2. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. *J Natl Cancer Inst*. 2008; 100:1179–83. [PubMed: 18695137]
3. Chiang AC, Massague J. Molecular basis of metastasis. *N Engl J Med*. 2008; 359:2814–23. [PubMed: 19109576]
4. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. *J Clin Oncol*. 1996; 14:2738–46. [PubMed: 8874335]
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature*. 2000; 406:747–52. [PubMed: 10963602]
6. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A*. 2001; 98:10869–74. [PubMed: 11553815]
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A*. 2003; 100:8418–23. [PubMed: 12829800]
8. Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. *Annu Rev Pathol*. 2008; 3:67–97. [PubMed: 18039137]

9. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol.* 2007; 25:5287–312. [PubMed: 17954709]
10. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med.* 1971; 285:1182–6. [PubMed: 4938153]
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature.* 2000; 407:249–57. [PubMed: 11001068]
12. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone marrow derived endothelial and a hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nature Medicine.* 2001; 7:1194–201.
13. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. *Nature.* 2005; 438:820–7. [PubMed: 16341007]
14. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. *Science.* 2008; 319:195–8. [PubMed: 18187653]
15. Fujita K, Nakayama M, Nakai Y, et al. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. *Cancer Sci.* 2009; 100:1047–50. [PubMed: 19385972]
16. Taylor M, Rossler J, Geoerger B, et al. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. *Clin Cancer Res.* 2009; 15:4561–71. [PubMed: 19605404]
17. Gao D, Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. *Trends Mol Med.* 2009; 15:333–43. [PubMed: 19665928]
18. Roodhart JM, Langenberg MH, Daenen LG, Voest EE. Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. *Biochim Biophys Acta.* 2009; 1796:41–9. [PubMed: 19409450]
19. Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. *Cancer Res.* 2006; 66:7341–7. [PubMed: 16849585]
20. Furstemberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. *Br J Cancer.* 2006; 94:524–31. [PubMed: 16450002]
21. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. *J Clin Oncol.* 2005; 23:5688–95. [PubMed: 16110028]
22. Richter-Ehrenstein C, Rentzsch J, Runkel S, Schneider A, Schonfelder G. Endothelial progenitor cells in breast cancer patients. *Breast Cancer Res Treat.* 2007; 106:343–9. [PubMed: 17972175]
23. Naik RP, Jin D, Chuang E, et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. *Breast Cancer Res Treat.* 2008; 107:133–8. [PubMed: 18043899]
24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009; 45:228–47. [PubMed: 19097774]
25. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. *Nat Rev Cancer.* 2006; 6:835–45. [PubMed: 17036040]
26. Mancuso P, Antoniotti P, Quarna J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. *Clin Cancer Res.* 2009; 15:267–73. [PubMed: 19118054]
27. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. *Cancer Cell.* 2008; 14:263–73. [PubMed: 18772115]
28. Farace F, Massard C, Borghi E, Bidart JM, Soria JC. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. *Ann Oncol.* 2007; 18:1421–2. [PubMed: 17693656]

29. Khan SS, Solomon MA, McCoy JP Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. *Cytometry B Clin Cytom.* 2005; 64:1–8. [PubMed: 15668988]
30. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. *Blood.* 2004; 103:921–6. [PubMed: 14525788]
31. Friedrich EB, Werner C, Walenta K, Bohm M, Scheller B. Role of extracellular signal-regulated kinase for endothelial progenitor cell dysfunction in coronary artery disease. *Basic Res Cardiol.* 2009; 104:613–20. [PubMed: 19363666]
32. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. *J Clin Oncol.* 28:49–55.
33. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. *J Clin Oncol.* 28:780–7.
34. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). *Cancer.* 116:1027–32.
35. Jain S, Ward M, Chuang E, Cigler T, Moore A, Donovan D, et al. The effect of tetrathiomolybdate (TM) on circulating endothelial progenitor cells in women at moderate to high risk of breast cancer recurrence. *Proc Breast Cancer Symp.* 2010 abstr 297.

Translational Relevance

Bone marrow-derived VEGFR1⁺ hematopoietic progenitor cells (HPCs) and VEGFR2⁺ endothelial progenitor cells (EPCs) are critical in modulating the angiogenic switch, the transition of avascular micrometastases to vascularized macrometastatic disease in preclinical models. This is the first report confirming these preclinical models in a well-annotated cohort of breast cancer patients who metastasized while on study. That is, in patients who relapsed, we observed a striking increase in HPCs followed by a similarly striking increase in EPCs immediately prior to overt relapse. We also explored if these cells could predict therapeutic response in metastatic breast cancer patients and demonstrated that HPCs predicted therapeutic response in the metastatic cohort. Monitoring and targeting of these cells may be an important addition to the management of breast cancer patients if a specific therapeutic intervention is formulated to prevent both relapse and disease progression.

Figure 1.

This schema represents the 2 studies from which the observations are pooled. Study 1 contained 2 cohorts of breast cancer patients (stages 1 to 3 and metastatic patients) while Study 2 represents stage 2 to 4 breast cancer patients without evidence of disease but at high risk of relapse.

Abbreviations: BC = breast cancer, NED = no evidence of disease, n= number of patients, t= number of treatment cycles, TM = tetrathiomolybdate, ^a = Patients may have had more than 1 response throughout study, ^b = 1 patient rendered NED with therapy then relapsed, thereafter comprising the “relapsed” group, ^c = 4 pts evaluable

Figure 2. Significant increase in (A) VEGFR1⁺ HPCs and (B) VEGFR2⁺ EPCs is observed from baseline (white bar) immediately prior to relapse (black bar) in 7 breast cancer patients without evidence of disease at study entry.

Figure 3.

Characteristic pattern of VEGFR1⁺ and VEGFR2⁺ hemangiogenic progenitor cells is observed prior to relapse of breast cancer who are without evidence of disease at study entry, *i.e.* an initial surge of the VEGFR1⁺ HPCs is followed by a surge of the VEGFR2⁺ EPCs prior to overt relapse. Median values of baseline, HPC surge, EPC surge, and at relapse of relapsed patients (n=3) are shown here. Parenthesis, range in months *prior* to overt relapse.

Figure 4.

Change in VEGFR1⁺ HPCs and VEGFR2⁺ EPCs from baseline to a subsequent time point stratified by response to therapy, as defined by (A,B) progression of disease, (C,D) responding disease, and (E,F) stable disease. 1 data point is outside the axis limits in (A,B) graphs and 2 in (C,D) graphs. Horizontal line, median values.

Table I

Patient characteristics at study entry

	Study 1	Study 2	Pooled
Total patients, <i>n</i>	91	41	132
Median age, <i>y</i> (range)	48 (26–74)	51 (29–66)	49 (26–74)
Stage 1, <i>n</i> (%)	16 (17.6%)	0 (0%)	16 (12.1%)
Stage 2, <i>n</i> (%)	24 (26.4%)	3 (7.3%)	27 (20.5%)
Stage 3, <i>n</i> (%)	21 (23.1%)	26 (63.4%)	47 (35.6%)
Stage 4, <i>n</i> (%)	30 (33.0%)	12 (29.2%)	42 (31.8%)
<i>De novo</i> , <i>n</i>	8	0	8
Established metastasis, <i>n</i>	22	0	22
No evidence of disease, <i>n</i>	0	12	12
Adjuvant patients, <i>n</i>	61	29	90
Chemotherapy	60	28	88
Anthracycline only	3	1	4
Anthracycline and taxane	25	27	52
Chemo and trastuzumab	21	5	26
Metastatic patients, <i>n</i>	30	12	42
Median chemo regimens, <i>n</i> (range)	2 (0–6)	1 (0–3)	1 (0–6)
Taxanes	22	6	28
Vinorelbine	9	0	9
Gemcitabine	6	0	6
Capecitabine	22	2	24
Ixabepilone	8	0	8
Median hormone regimens, <i>n</i> (range)	1 (0–4)	1 (0–4)	1 (0–4)
Median biologics, <i>n</i> (range)	0 (0–2)	0 (0–1)	0 (0–2)

Median VEGFR1⁺ HPC/mL and VEGFR2⁺ EPC/mL by therapeutic response in stage 4 patients

Table II

Clinical Response <i>t</i> =40	Median HPC/mL		p-value	Median EPC/mL		p-value
	Baseline	Response		Baseline	Response	
Responding disease <i>t</i> =12	6147	633	0.05	46	23	0.41
Range	912–85070	47–18065		0–197	0–105	
Stable disease <i>t</i> =8	1309	1188	0.31	78	29	0.15
Range	390–55377	135–20690		11–484	9–331	
Progression of disease <i>t</i> =20	1696	5124	0.0009	26	71	0.10
Range	10–16470	374–77605		0–560	0–615	